Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 21, 2017; 23(7): 1262-1267
Published online Feb 21, 2017. doi: 10.3748/wjg.v23.i7.1262
Published online Feb 21, 2017. doi: 10.3748/wjg.v23.i7.1262
Total patients | Survivors | Non-survivors | P value | |
(n = 23) | (n = 13) | (n = 10) | ||
Age, yr | 61.0 (51.0-66.0) | 61.0 (53.0-69.0) | 52.0 (38.0-62.0) | 0.74 |
Male | 11 (48) | 6 (46) | 5 (50) | 0.86 |
Comorbidities | ||||
Hypertension | 6 (26) | 5 (38) | 1 (10) | 0.11 |
Diabetes mellitus | 2 (9) | 2 (17) | 0 (0) | 0.17 |
Chronic kidney disease | 0 (0) | 0 (0) | 0 (0) | |
Chronic liver disease | 0 (0) | 0 (0) | 0 (0) | |
Time from ingestion to hospitalization, d | 3.0 (3.0-3.0) | 3.0 (3.0-3.0) | 3.0 (3.0-3.0) | 0.26 |
Vital signs, initial | ||||
SBP, mmHg | 126.0 (112.0-134.0) | 122.0 (116.0-133.0) | 128.5 (112.0-146.0) | 0.47 |
DBP, mmHg | 71.0 (66.0-89.0) | 78.0 (67.0-90.0) | 69.5 (66.5-77.5) | 0.59 |
Heart rate, min | 78.0 (65.0-89.0) | 70.0 (63.0-87.0) | 94.5 (78.5-116.2) | 0.03 |
Respiratory rate, min | 20.0 (18.0-20.0) | 20.0 (18.0-20.0) | 20.0 (20.0-20.0) | 0.24 |
Temperature, °C | 36.6 (36.1-37.1) | 36.6 (36.2-36.1) | 36.6 (36.1-37.0) | 0.56 |
SpO2, % | 98.0 (97.0-99.0) | 98.0 (97.0-99.0) | 98.0 (97.0-99.0) | 0.36 |
Laboratory data | ||||
WBC, × 103/mL | 7.5 (5.8-12.2) | 7.0 (6.0-8.3) | 11.3 (6.0-15.6) | 0.11 |
Hemoglobin, g/dL | 14.1 (13.0-15.4) | 14.2 (13.4-15.4) | 12.8 (10.6-15.0) | 0.12 |
Platelet, × 103/mL | 172.0 (115.0-223.0) | 197.0 (156.0- 223.0) | 125.5 (87.3-181.3) | 0.06 |
BUN, mg/dL | 21.0 (9.0-33.0) | 15.0 (10.0-29.0) | 23.0 (10.3-31.5) | 0.66 |
Cr, mg/dL | 0.90 (0.60-1.30) | 0.70 (0.60-0.90) | 1.70 (1.00-1.80) | 0.23 |
AST, IU/L | 4568.0 (863.0-6933.0) | 4568.0 (702.0-5471.0) | 5650.0 (2065.3-8155.8) | 0.19 |
ALT, IU/L | 4750.0 (1561.0-5543.0) | 4436.0 (1561.0-5543.0) | 5002.0 (2235.5-6584.3) | 0.31 |
γ-GT, IU/L | 38.0 (23.0-71.0) | 26.0 (13.0-53.0) | 55.50 (39.0-85.0) | 0.35 |
ALP, IU/L | 85.0 (71.0-162.0) | 71.0 (69.0-81.0) | 165.0 (151.0-208.0) | < 0.01 |
Total bilirubin, mg/dL | 3.50 (1.70-6.40) | 1.80 (1.60-3.00) | 6.80 (6.00-8.80) | < 0.01 |
Indirect/direct bilirubin ratio | 1.79 (0.5-3.08) | 2.45 (1.06-3.84) | 0.99 (0.54-1.44) | < 0.01 |
PT-INR, s | 2.90 (1.40-8.80) | 1.60 (1.20-2.60) | 9.70 (7.60-14.30) | < 0.01 |
aPTT, s | 41.4 (28.9-54.3) | 29.1 (28.9-35.3) | 54.6 (52.6-71.4) | 0.01 |
Management | ||||
Vasopressor | 7 (30) | 0 (0) | 7 (70) | < 0.01 |
Mechanical ventilation | 6 (26) | 0 (0) | 6 (60) | < 0.05 |
CRRT | 5 (22) | 0 (0) | 5 (50) | < 0.01 |
OR | 95%CI | P value | |
Alkaline phosphatase | 1.21 | (0.91, 1.60) | 0.20 |
Total bilirubin | 3.58 | (1.25, 10.22) | 0.02 |
Indirect/direct bilirubin ratio | 0.13 | (0.02, 0.94) | 0.04 |
Prothrombin time | 789.00 | - | 0.98 |
Activated partial thromboplastin time | 1.30 | (1.04, 1.63) | 0.02 |
- Citation: Kim T, Lee D, Lee JH, Lee YS, Oh BJ, Lim KS, Kim WY. Predictors of poor outcomes in patients with wild mushroom-induced acute liver injury. World J Gastroenterol 2017; 23(7): 1262-1267
- URL: https://www.wjgnet.com/1007-9327/full/v23/i7/1262.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i7.1262